Takeda Pharmaceutical (TAK) Change in Receivables (2018 - 2026)

Takeda Pharmaceutical has reported Change in Receivables for 9 years, with the latest figure at -$445.3 million in Q2 2026.

• On a quarterly basis, Change in Receivables fell 233.99% year-over-year to -$445.3 million in Q2 2026; TTM through Jun 2026 was -$1.2 billion, a 567.65% decrease from a year earlier, with the FY2026 full-year figure at -$447.4 million, down 15.59% from the prior year.
• Change in Receivables was -$445.3 million for Q2 2026 at Takeda Pharmaceutical, up from -$621.8 million in the prior quarter.
• The five-year high for Change in Receivables was $516.1 million in Q1 2023, with the low at -$659.4 million in Q2 2023.
• Average Change in Receivables over 5 years is -$14.2 million, with a median of $8.4 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Change in Receivables soared 208.35% in 2025, then plunged 584.76% in 2026.
• Over 5 years, Change in Receivables stood at $90.4 million in 2022, then advanced by 6.93% to $96.7 million in 2023, then fell by 13.75% to $83.4 million in 2024, then slumped by 185.24% to -$71.1 million in 2025, then plunged by 526.59% to -$445.3 million in 2026.
• The last three Change in Receivables figures came in at -$445.3 million (Q2 2026), -$621.8 million (Q1 2026), and -$71.1 million (Q4 2025), per Business Quant data.